期刊文献+

磁共振动态增强成像对卵巢肿瘤血管生成及侵袭的诊断价值 被引量:8

Diagnostic value of dynamic contrast enhanced MRI in the angiogenesis and invasion of ovarian tumors
原文传递
导出
摘要 目的:探讨磁共振动态增强成像( DCE-MRI)对卵巢肿瘤血管生成及侵袭的诊断价值。方法回顾性分析98例经手术病理证实的卵巢肿瘤患者术前且未经治疗的DCE-MEI影像资料,据药物动力学模型获得病灶的对比剂容积转移常数( Ktrans )、血管外细胞外间隙( Ve)值,采用免疫组织化学检测卵巢肿瘤组织血管内皮生长因子(VEGF)、基质金属蛋白酶-2(MMP-2)表达,并对DCE-MRI参数与免疫组织化学结果进行相关性分析。结果卵巢恶性肿瘤组织中VEGF与MMP-2表达明显高于良性肿瘤( P<0.05);卵巢恶性肿瘤Ktrans与Ve均值亦明显高于良性肿瘤,差异具有统计学意义( P<0.05);Ktrans、Ve与VEGF、MMP-2表达均呈正相关。结论 DCE-MRI能够无创在体评价卵巢肿瘤血管生成及侵袭情况,对临床治疗及预后评估具有重要意义。 Objective To evaluate the diagnostic value of dynamic contrast enhanced MRI (DCE-MRI)in angiogenesis and invasion of ovarian tumors .Methods 98 patients with pathological-confirmed ovarian tumors without any treatment underwent plain MRI and DCE-MRI before operation .The plain MR images and DCE-MRI data were retrospectively analyzed .Value of Ktrans and Ve was detected by pharmacokinetic model .The expression of VEGF and MMP-2 in ovarian tumors was examined by immunohistochemistry .The correlation between DCE-MRI parameters and immunohistochemical results was analyzed .Results The expression of VEGF and MMP-2 was sig-nificantly higher in the malignant group compared with that in the benign group (both P〈0.05).The value of Ktrans and Ve was significantly lower in the benign group compared with that in the malignant group ( both P〈0.05) .The value of Ktrans and Ve was positively correlated with the expression of VEGF and MMP-2.Conclusion DCE-MRI can noninvasively evaluate the angiogenesis and invasion of ovarian tumors in vivo , which has important signifi-cance for clinical treatment and prognostic assessment .
出处 《中华内分泌外科杂志》 CAS 2015年第2期160-163,共4页 Chinese Journal of Endocrine Surgery
关键词 磁共振动态增强 卵巢肿瘤 血管生成 侵袭 血管内皮生长因子 基质金属蛋白酶-2 Dynamic contrast enhanced magnetic resonance imaging Ovarian tumors Angiogene-sis Invasion VEGF MMP-2
  • 相关文献

参考文献12

  • 1苏青青,段早辉,毛青青,张先水,吴春江,林国刚,叶义.卵巢癌磁共振影像误诊分析[J].江西医药,2014,49(2):171-172. 被引量:5
  • 2Hensley H, Quinn BA, Wolf RL, et al. Magnetic resonance ima-ging for detection and determination of tumor volume in a geneti-cally engineered mouse model of ovarian cancer [ J ]. Cancer BiolTher,2007,6(11) : 1717-1725.
  • 3Tuncbilek N,Tokatli F,Altaner S,et al. Prognostic value DCE-MRI parameters in predicting factor disease free survival and over-all survival for breast cancer patients[ J]. Eur J radiol,2012, 81(5):863-867.
  • 4Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining ofHaras oncogene product in normal, benign, and malignant humanpancreatic tissues[ J]. Hum Pathol,1990,21 (6) :607-612.
  • 5方如旗,曹代荣,翁淑萍,邢振.磁共振动态增强及扩散加权成像对复杂性卵巢肿瘤定性诊断的价值[J].临床放射学杂志,2014,33(11):1705-1709. 被引量:28
  • 6Ahn SJ, An CS, Koom WS, et al. Correlations of 3T DCE-MRIquantitative parameters with microvessel density in a human-color-ectal-cancer xenograft mouse model[ J]. Korean J Radiol, 2011,l2(6):722-730.
  • 7Chase DM, Sill MW, Monk BJ, et al. Changes in tumor bloodflow as measured by dynamic contrast-enhanced magnetic reso-nance imaging( DCE-MRI) may predict activity of single agent bev-acizumab in recurrent epithelial ovarian (EOC) and primary perito-neal cancer ( PPC ) patients : an exploratory analysis of a gynecolog-ic oncology group phase II study [ J ]. Gynecologic Oncology,2012,126(3):375-380.
  • 8朱银芳,谭布珍.卵巢癌相关转移基因的研究进展[J].肿瘤,2014,34(9):875-878. 被引量:4
  • 9陶方方,沈敏鹤,阮善明.卵巢癌转移相关的分子机制探讨[J].中华中医药学刊,2014,32(10):2378-2381. 被引量:4
  • 10张艳艳,李红雨,张慧,姚俊阁,郭欢欢.MTDH和VEGF在上皮性卵巢癌中的表达及临床意义[J].临床肿瘤学杂志,2014,19(1):18-22. 被引量:12

二级参考文献44

  • 1Yan-Ni Xi,Xiao-Yan Xin,Hong-Mei Ye.Effects of HMGA2 on malignant degree,invasion,metastasis,proliferation and cellular morphology of ovarian cancer cells[J].Asian Pacific Journal of Tropical Medicine,2014,7(4):289-292. 被引量:7
  • 2单军,徐坚民,龚静山,王晓玫,徐宏里,冯晓凤.早期增强MRI对良恶性卵巢肿瘤的鉴别诊断价值[J].中华放射学杂志,2003,37(11):1001-1006. 被引量:41
  • 3陈一东,李仲明,刘卫红,叶丰,周晓琳,冯芳.易误诊为肝硬化腹水的卵巢癌[J].临床误诊误治,2005,18(11):816-817. 被引量:1
  • 4Bilynskyj BT. The breast cancer treatment as a marker of progress in oncology [J].Exp Oneol, 2010, 32 (3): 190- 194.
  • 5Alvarez RH, Guarneri V, Icli F, et ai. Bevacizumab treat- ment for advanced breast cancer [J]. Oncologist, 2011, 16 (12) : 1684-1697.
  • 6Lu N, Ling Y, Gao Y, et al. Endostar suppresses invasion through downregulating the expression of matrix metallopro- teinase-2/9 in MDA-MB-435 human breast cancer cells [J]. Exp Biol Med (Maywood), 2008, 233(8) : 1013-1020.
  • 7Thielemann A, Kopczynski Z, Filas V, et al. The determina- tion of VEGF and MVD, among patients with primary breast cancer [J]. Pathol Oncol Res, 2008, 14(2): 137-144.
  • 8Kusaba H, Saijo N. A summary report of response evaluation criteria in solid tumors (RECIST criteria) [J]. Gan To Ka- gaku Ryoho, 2000, 27(1): 1-5.
  • 9Ge YL, Zhang X, Zhang JY, et al. The mechanisms on apop- tosis by inhibiting VEGF expression in human breast cancer cells [J]. Int Immunopharmacol, 2009, 9(4): 389-395.
  • 10Sipola A, Nelo K, Hautala T, etal. Endostatin inhibits VEGF-A induced osteoclastic bone resorption in vitro [J]. BMC Musculoskelet Disord, 2006, 7: 56.

共引文献51

同被引文献65

引证文献8

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部